Stricter criteria will now apply to venue selection in ANDA patent disputes
In the way it has cleared up TC Heartland uncertainties relating to Hatch-Waxman litigation, the CAFC will have disappointed branded pharma companies
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.